Mohler JLLee RJAntonarakis ES. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2018. To view the most recent version visit NCCN.org. Accessed October 1 2018.
Pilepich MVWinter KLawton CA. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–1290.
Widmark AKlepp OSolberg A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–308.
Hamdy FCDonovan JLLane JA. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–1424.
Bolla Mde Reijke TMVan Tienhoven G. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–2527.
Bill-Axelson AHolmberg LGarmo H. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.
Bilimoria KYStewart AKWinchester DP. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683–690.
Briganti AKarnes RJDa Pozzo LF. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 2011;59:832–840.
- Search Google Scholar
- Export Citation
)| false . , Briganti A , Karnes RJ , Da Pozzo LF Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. 2011; 59: 832– 840. 10.1016/j.eururo.2011.02.024 21354694
Tward JDKokeny KEShrieve DC. Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol 2013;3:234–240.
Rusthoven CGCarlson JAWaxweiler TV. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 2014;88:1064–1073.
Lin CCGray PJJemal A. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst 2015;107:djv119.
Ghavamian RBergstralh EJBlute ML. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223–1227; discussion 1227–1228.
Engel JBastian PJBaur H. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754–761.
Evans JDJethwa KROst P. Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol 2018;8:28–39.
Akin-Akintayo OOJani ABOdewole O. Change in salvage radiotherapy management based on guidance with FACBC (Fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer. Clin Nucl Med 2017;42:e22–28.
Byrne KEade TKneebone A. Delineating sites of failure following post-prostatectomy radiation treatment using 68-Ga-PSMA-PET. Radiother Oncol 2018;126:244–248.
Rodrigues GBae KRoach M. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys 2011;80:445–452.
Tai PTonita JWoitas C. Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen. Int J Radiat Oncol Biol Phys 2012;83:e525–530.
Vanasupa BPPaquette ELWu H. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. Urol Oncol 2002;7:167–172.
Ou YCChen JTCheng CL. Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml. Jpn J Clin Oncol 2003;33:574–579.
Wiebe ERodrigues GLock M. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml. Can J Urol 2008;15:4078–4083.
Bill-Axelson AHolmberg LRuutu M. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–1717.
Lawton CAFLin XHanks GE. Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys 2017;98:296–303.
Muralidhar VMahal BARose BS. Disparities in the receipt of local treatment of node-positive prostate cancer. Clin Genitourin Cancer 2017;15:563–569.
McDavid KTucker TCSloggett A. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med 2003;163:2135–2144.
Gilligan T. Social disparities and prostate cancer: mapping the gaps in our knowledge. Cancer Causes Control 2005;16:45–53.
Mahal BAAizer AAZiehr DR. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 2014;84:386–392.
Mahal BAAizer AAZiehr DR. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis 2014;17:273–279.
Falchook ADSalloum RGHendrix LH. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys 2014;89:243–248.
Prasad SMGu XLipsitz SR. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer 2012;118:1260–1267.